Veraxa Biotech AG(VRXA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 4.67 | EPS (ttm) | 0.21 | Insider Own | 75.07% | Shs Outstand | 147.7M | Perf Week | -1.02% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.08% | Shs Float | 36.8M | Perf Month | -27.03% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | - | Inst Own | 0.33% | Short Float | 0.29% | Perf Quarter | -49.25% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | 56.09% | Short Ratio | 0.4 | Perf Half Y | -92.21% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | 2.52% | Short Interest | 0.11M | Perf YTD | -90.63% |
| Book/sh | -2.25 | P/C | 4923.01 | EPS past 3/5Y | - | ROE | 5.72% | 52W High | -96.35% ($27.36) | Perf Year | -90.47% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 5.23% ($0.95) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.24% | Gross Margin | - | Volatility(W/M) | 6.42% 10.35% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0 | EPS Q/Q | -91.03% | Profit Margin | - | RSI (14) | 36.39 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0 | Sales Q/Q | - | SMA20 | -9.41% ($1.1) | Beta | 0.24 | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -27.26% ($1.37) | Rel Volume | 0.36 | Prev Close | $0.98 |
| Employees | 3 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -85.95% ($7.12) | Avg Volume(3M) | 0.27M | Price | $1 |
| IPO | 2024/9/30 | Option/Short | No/Yes | Trades | 265 | Volume | 95,383 | Change | 2.01% |
🧬 A global clinical-stage biotech company developing next-generation antibody-based cancer therapeutics and antibody-drug conjugates (ADCs). Headquartered in Switzerland, it is building an innovative oncology pipeline based on a platform technology that selectively targets tumor sites to reduce side effects.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 36% of its average volume.
VRXA earns moderately but has a weak balance sheet
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $467. Peers typically go for $1,456.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
It ranks #324 of 594 in the industry
Based on market cap of $148M.
VRXA#324 Veraxa Biotech AG $148M PER 4.7 
STRO#325 Sutro Biopharma Inc $147M PER - 
MSLE#326 Satellos Bioscience Inc $146M PER - 
MOLN#327 Molecular Partners AG ADR $146M PER - 
TARA#327 Protara Therapeutics Inc $146M PER - 
FAQ
What kind of company is VRXA?
VRXA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRXA?
The market cap of VRXA is approximately $148M, ranking 4,228 within its sector.
What is the P/E ratio of VRXA?
VRXA has a P/E ratio of approximately 4.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VRXA?
VRXA has recorded a 52-week high of $27.36 and a low of $0.95.
